Friday, December 23, 2016

BRIEF-Helix Biopharma successfully out-licenses late stage Biphasix technology

* Under terms of agreement, Xisle has paid an up-front fee

and agreed to subsequent milestone payments

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)